This market study report presents a detailed segmentation of the global drug-eluting stent market by geography (Americas, APAC, and EMEA). The leading vendors in the market are Abbott Laboratories, Biosensors International, Boston Scientific, Medtronic, and Terumo.
Technavio has released a new market research report on the global drug eluting stent market, which is expected to grow at a CAGR of more than 3% between 2016 and 2020. With an increase in the prevalence of atherosclerosis diseases, the market for drug-eluting stent products will have a positive outlook until the end of 2020. The growing prevalence of these diseases is due to factors such as smoking, obesity, alcohol consumption, and unhealthy lifestyle. Furthermore, the rapidly increasing older population is driving the market because aging increase the chances of developing cardiovascular diseases including atherosclerosis. The America is the largest market for drug-e;uting stent, accountingfor 41% of the total market share.
The new industry research report from Technavio discusses in detail the key drivers and trends responsible for the growth of this market and its sub-segments.
“A hybrid procedure is an innovative approach that combines minimally invasive coronary artery bypass surgery with catheter-based coronary intervention. After the bypass surgery, the cardiologist performs angioplasty to restore the normal blood flow to the coronary arteries. Drug-eluting stenting is used to reduce re-blockage of the artery. This hybrid procedure is performed together, rather than as separate operations, which helps save time and cost. This recent preference for hybrid procedures is expected to drive the market growth for drug-eluting stents during the forecast period,” says Brahadeesh Chandrasekaran, Healthcare & Lifesciences, Technavio Research
Drug-eluting stents reduce the risk of adverse cardiac events such as blockages and strokes that occur after patients undergo stent procedures. The advantage of drug-eluting stents is that the risk of restenosis or the growth of scar tissue in the arterial lining is quite minimal. Earlier, bare-metal stents were used to prevent the collapse of arteries. However, it was observed that in approximately 25% of the cases, arteries got re-blocked after the placement of a bare-metal stent. On the other hand, a drug-eluting stent offers the same benefits of bare-metal stents with an additional feature of releasing a drug from time to time to reduce the chances of re-clogging. Further, clinical studies have shown that using a drug-eluting stent reduces the occurrence of re-narrowing by 8%-10%.
The leading vendors in the global drug eluting stent market are Abbott Laboratories, Biosensors International, Boston Scientific, Medtronic, and Terumo. This market is highly fragmented due to the presence of several well-established vendors. The competition is expected to intensify with an increase in product portfolio extensions with next-generation products, technological innovations, and mergers and acquisitions.
A more detailed analysis is available in the Technavio report, Global Drug Eluting Stent Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
